Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the ...

Options traders leaned bearish on LLY stock, but market demand data reveals conditional odds that may support near-term ...

Novo Nordisk (NVO) and Eli Lilly & Co. (LLY), the global leaders in obesity medications, are now facing their first major ...

CVS Caremark will stop covering Eli Lilly's Zepbound, a weight loss drug, due to insurance company changes. Patients are outraged and concerned.

Eli Lilly poised for 30-50% growth in 12 months with a strong value and growth nexus. Click here to read more on LLY stock.

Eli Lilly (NYSE: LLY) has been on fire over the past two years. The drugmaker has generated excellent financial results and ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

Answering a random call was the serendipitous connection that led to Purdue Extension's new Downing Endowment for Community ...

Novo Nordisk's top executives ignored internal warnings that the company was not sufficiently prepared for the launch of its ...